Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.
Back
Assessing AFib Burden and BTK Inhibitor Effects in CLL/SLL
Michael G. Fradley, MD, and colleagues spotlight the impact of AFib and BTK inhibitor selection in patients with CLL or SLL.
Assessing AFib Burden and BTK Inhibitor Effects in CLL/SLL
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5